Your browser doesn't support javascript.
loading
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry.
Jones, Gemma N; Rooney, Claire; Griffin, Nicola; Roudier, Martine; Young, Lucy A; Garcia-Trinidad, Antonio; Hughes, Gareth D; Whiteaker, Jeffrey R; Wilson, Zena; Odedra, Rajesh; Zhao, Lei; Ivey, Richard G; Howat, William J; Harrington, Elizabeth A; Barrett, J Carl; Ramos-Montoya, Antonio; Lau, Alan; Paulovich, Amanda G; Cadogan, Elaine B; Pierce, Andrew J.
Afiliación
  • Jones GN; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK. Gemma.Jones@astrazeneca.com.
  • Rooney C; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Griffin N; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Roudier M; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Young LA; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Garcia-Trinidad A; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Hughes GD; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Whiteaker JR; Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA.
  • Wilson Z; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Odedra R; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Zhao L; Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA.
  • Ivey RG; Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA.
  • Howat WJ; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Harrington EA; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Barrett JC; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Ramos-Montoya A; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Lau A; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Paulovich AG; Clinical Research Division, Fred Hutchinson Cancer Research Centre, Seattle, WA, USA.
  • Cadogan EB; Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Cambridge, UK.
  • Pierce AJ; Translational Sciences, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK. Andrew.Pierce@astrazeneca.com.
Br J Cancer ; 119(10): 1233-1243, 2018 11.
Article en En | MEDLINE | ID: mdl-30385821
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Espectrometría de Masas / Proteínas de la Ataxia Telangiectasia Mutada Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Espectrometría de Masas / Proteínas de la Ataxia Telangiectasia Mutada Límite: Animals / Humans Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido